Ozempic and other GLP-1 RAs could slow progression of some cancers, data suggest

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 receptor (GLP-1R) expression was associated with overall survival, suggesting that GLP-1 signaling could be involved in the progression of these cancers.